Successful treatment of persistent MRSA bacteremia using high-dose daptomycin combined with rifampicin

Hideharu Hagiya, Tomohiro Terasaka, Kosuke Kimura, Asuka Satou, Kikuko Asano, Koichi Waseda, Yoshihisa Hanayama, Fumio Otsuka

Research output: Contribution to journalArticle

5 Citations (Scopus)


We herein report a case of persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia that was successfully treated with combination therapy consisting of high-dose daptomycin (DAP, 10 mg/kg) and rifampicin. The patient’s condition was complicated with multiple infectious foci, including an iliopsoas abscess and epidural abscess, as well as discitis and spondylitis at the cervical, thoracic and lumbar levels. Monotherapy treatments with vancomycin, linezolid and usual-dose DAP were all ineffective. It has been shown that usual-dose DAP administration may result in the emergence of a resistant strain and treatment failure. We would like to emphasize the importance of high-dose DAP therapy for MRSA bacteremia, a condition with a potentially high mortality rate.

Original languageEnglish
Pages (from-to)2159-2163
Number of pages5
JournalInternal Medicine
Issue number18
Publication statusPublished - Sep 1 2014



  • Butyrylcholinesterase (BChE) deficiency
  • Daptomycin (DAP)
  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Staphylococcus aureus bacteremia (SAB)

ASJC Scopus subject areas

  • Internal Medicine

Cite this